Dermatomyositis Clinical Trial
Official title:
Correlation of "Myositis Functional Index-3 (Fi-3)" With Muscle Function Assessed by Isokinetic Dynamometry and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
Idiopathic inflammatory myopathies lead to important functional limitations resulting from the loss of muscle strength and endurance, especially in the hip and shoulder, which leads to a significant loss of quality of life for patients. The aim of this study is to correlate the "Myositis Functional Index-3 (FI-3)" with muscle function assessed by computerized isokinetic dynamometry, electromyography and magnetic resonance through an observational study; and to compare the effects of a repetitive task training program with a resistance exercise program through an interventional study in patients with inflammatory myopathies. It is expected that FI-3 will present a good correlation with muscle function assessed by computerized isokinetic dynamometry and electromyography, given its reduced cost and less time spent on evaluation. It is also expected to demonstrate that repetitive task training is as efficient and safe as resistance exercises.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | September 1, 2023 |
Est. primary completion date | September 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - diagnosis of polymyositis or dermatomyositis (Bohan and Peter criteria) - age =18 years - duration of disease since diagnosis for more than six months - stable medication =3 months - chronic inactive or mildly active but stable myositis for at least 3 months prior to observation - Health Assessment Questionnaire (HAQ) =0.5 Exclusion Criteria: - serious cardiac or pulmonary conditions - severe osteoporosis - unable to exercise - neoplasm - cognitive disorders - acute or chronic infection |
Country | Name | City | State |
---|---|---|---|
Brazil | Samira Tatiyama Miyamoto, PhD | Vitória | ES |
Lead Sponsor | Collaborator |
---|---|
Federal University of Espirito Santo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | muscle performance endurance | "Myositis Functional Index-3 (FI-3)"; number of repetition of each muscle group task from 0-60 | 2 years | |
Primary | computerized muscle endurance test | "isokinetic dynamometry"; number of repetitions of shoulder and hip flexion until exhaustion | 2 years | |
Secondary | manual muscle strength test | "Manual Muscle Test 8"; Score from 0-10, higher scores mean a better outcome | 2 years | |
Secondary | computerized muscle strength test | "isokinetic dynamometry"; mean of 3 concentric peak torque of shoulder and hip flexion | 2 years | |
Secondary | cardiopulmonary capacity | "6-minute walk test"; greater time mean a better outcome | 2 years | |
Secondary | functional capacity | "Health Assessment Questionnaire"; Score from 0-3, score from 0-100, higher scores mean a worse outcome | 2 years | |
Secondary | quality of life level | "Medical Outcomes Short-Form Health Survey (SF-36)";Score from 0-100, higher scores mean a better outcome | 2 years | |
Secondary | disease activity by physician | "Physician Global Assessment (PGA)"; Score from 0-10, higher scores mean a worse outcome | 2 years | |
Secondary | disease activity by patient | "Subjective Global Assessment (SGA)"; Score from 0-10, higher scores mean a worse outcome | 2 years | |
Secondary | disease activity questionnaire | "Myositis Disease Activity Assessment Tool (MDAAT)"; This is a combined tool that captures the physician's assessment of disease activity of various organ systems using the 0-4 scale and a visual analog scale (VAS) from 0-10cm | 2 years | |
Secondary | laboratory parameters of disease activity I | "creatine phosphokinase"; units/L | 2 years | |
Secondary | laboratory parameters of disease activity II | aldolase; units/L | 2 years | |
Secondary | disease damage | "Myositis Damage Index (MDI)"; 10 cm visual analogue scale scores for each of the eleven individual organ systems | 2 years | |
Secondary | muscle activation | electromyography during shoulder and hip flexion; motor unit action potentials (MUAPs) | 2 years | |
Secondary | muscle damage | magnetic resonance imaging of thigh muscles; muscle damage and fatty infiltration | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
Not yet recruiting |
NCT06284954 -
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
|
Phase 2 | |
Completed |
NCT01906372 -
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
|
Phase 2 | |
Completed |
NCT01813617 -
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
Active, not recruiting |
NCT04723303 -
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
|
Early Phase 1 | |
Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05437263 -
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
|
Phase 3 | |
Active, not recruiting |
NCT04044690 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
|
Phase 3 | |
Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06004817 -
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
|
||
Recruiting |
NCT03324152 -
Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
Completed |
NCT02043548 -
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
|
Phase 2 | |
Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
Completed |
NCT04628936 -
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
|
Phase 2 | |
Recruiting |
NCT03293615 -
Exercise Capacity of Patients With Dermatomyosis
|
N/A | |
Recruiting |
NCT06462768 -
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
|